SU1227005A1 - Immunostimulator t-lymphocyte in treating neuroallergic disease - Google Patents
Immunostimulator t-lymphocyte in treating neuroallergic diseaseInfo
- Publication number
- SU1227005A1 SU1227005A1 SU802970290A SU2970290A SU1227005A1 SU 1227005 A1 SU1227005 A1 SU 1227005A1 SU 802970290 A SU802970290 A SU 802970290A SU 2970290 A SU2970290 A SU 2970290A SU 1227005 A1 SU1227005 A1 SU 1227005A1
- Authority
- SU
- USSR - Soviet Union
- Prior art keywords
- immunostimulator
- neuroallergic
- lymphocyte
- disease
- treating
- Prior art date
Links
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Применение галаскорбина в качестве иммуностимул тора Т-лнмфощ^тов при лечении нейроаллергическнх эа- болеваний.(ЛUse of galascorbine as an immunostimulant of T-medication in the treatment of neuro-allergic diseases. (L
Description
hO NDhO ND
« "
Изобретение от оснтс к области медицины, в частности к невропатологии и клинической иммунологии, и может быть использовано при лечении нейтроаллергических заболеваний.The invention is from the field of medicine, in particular to neuropathology and clinical immunology, and can be used in the treatment of neutroallergic diseases.
Целью изобретени вл етс изыскание иммуностимул тора Т-лимфоцитов дл лечени нейтроаллергических эаболеваний , не обладающего побочньм действием,The aim of the invention is to find an immunostimulator of T-lymphocytes for the treatment of neutroallergic diseases, which has no side effects,
П р и м е р« Больным рассе ннШ4 склерозом и больным преимущественно пищевой и бактериальной аллергией с поражением нервной системы (anriepгичаска энцефалопати ) назначают галаскорбин по 1,0 г 3 раза в сутки в течение 1,5-2 мес, В 1 группе больные продолжают получать дексаметазон по 4 мг} во П группе - пред270052PRI me R “Patients with disseminated nsH4 sclerosis and patients with predominantly food and bacterial allergies with damage to the nervous system (anrieggychasa encephalopati) are prescribed galascorbin 1.0 g 3 times a day for 1.5-2 months, patients in group 1 continue to receive dexamethasone 4 mg} in the P group - prev270052
ннзолон по 10-15 мг через день в сочетании с диазолином до 1 мес.nnzolon 10-15 mg every other day in combination with diazolin up to 1 month.
До назначени галаскорбина реакци бласттрансформации лимфоцитов 5 с ФГА в 1 группе составл ет 18,71 ±3,2%, Е-розеткообразующие клетки W 17,2±6,8% После лечени зтн же показатели составл ют соответственно 45,6±9j25% и 46,816,5%, Увелиte чение этих же показателей наблюдали у больных П группы.Before the administration of galascorbine, the reaction of blast transformation of lymphocytes 5 with PHA in group 1 was 18.71 ± 3.2%, E-rosette-forming cells W 17.2 ± 6.8% After treatment, the same indicators are respectively 45.6 ± 9j25% and 46.816.5%. An increase in these indicators was observed in patients with the P group.
При сравнительном изучении установлено , что процент стимул ций в опытах in vitro в сравнении с ФГА fS составл ет при использовании спленииа t ,8%, декариса А%,галаскорбийа 18%.In a comparative study, it was established that the percentage of stimulations in in vitro experiments compared with PHA fS is 18% when using splenia, decaris A%, and galascorbium.
После проведенного лечени у 881 больных аллергической энцефалопатией и течение 2 лет аллергических реак2« дай установлено не было.After treatment in 881 patients with allergic encephalopathy and for 2 years no allergic reactions were established.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SU802970290A SU1227005A1 (en) | 1980-07-07 | 1980-07-07 | Immunostimulator t-lymphocyte in treating neuroallergic disease |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SU802970290A SU1227005A1 (en) | 1980-07-07 | 1980-07-07 | Immunostimulator t-lymphocyte in treating neuroallergic disease |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SU1227005A1 true SU1227005A1 (en) | 1990-05-23 |
Family
ID=20913443
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SU802970290A SU1227005A1 (en) | 1980-07-07 | 1980-07-07 | Immunostimulator t-lymphocyte in treating neuroallergic disease |
Country Status (1)
| Country | Link |
|---|---|
| SU (1) | SU1227005A1 (en) |
-
1980
- 1980-07-07 SU SU802970290A patent/SU1227005A1/en active
Non-Patent Citations (1)
| Title |
|---|
| А,Н.Чередеев,Количественна и функциональна оценка Т- и В-систем иммунитета у человека, В кн. - Итоги науки и техники. Иммунологи . М,, 1976, т.4, с.124-160.Renoux G., Renoux М. "Effect immu- nostimulant d*un imidothiarole daus L'imraunis action des souris conte e'infection par Brucella abortus." C.R. Acad. Science, 1971, V. 272, p, 349-350.Е.Ф.Шамрай. Энергетический обмен при некоторых патологических состо ни х и п^ти его нормализации. 9 10, '1974, с.97-102. * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR940018089A (en) | Prevention and treatment for radiation damage of internal tissue | |
| KR930001902A (en) | Method for preparing fatty acid drug | |
| KR950007848A (en) | Treatment of Anxiety with (S)-(-)-α-ethyl-2-oxo-1-pyrrolidineacetamide | |
| US3928580A (en) | Injectable glycoproteins containing terminal {37 C{38 {0 ends of human immunoglobulins | |
| RU95101385A (en) | Products containing g-csf and tnf-binding protein | |
| GB2171302A (en) | Therapeutic hydroxyprolines | |
| SU1227005A1 (en) | Immunostimulator t-lymphocyte in treating neuroallergic disease | |
| US5331012A (en) | Topical pharmaceutical preparation for fever blisters and other viral infections and method of use | |
| JPH0475205B2 (en) | ||
| ATE92756T1 (en) | MEANS FOR TREATMENT OF KERATosis. | |
| Margolis et al. | Cure of Experimental Canine Blacktongue with Optimal and Minimal Doses of Nicotinic Acid: Three Figures | |
| Reid | Antivenene reaction following accidental sea-snake bite | |
| US4250168A (en) | Cold sore treatment method | |
| DE2221281C3 (en) | Pharmaceutical preparations with anti-inflammatory and analgesic effects | |
| JP2002519007A (en) | Alkylamines and their precursors as specific modulators of human gamma-delta T cell function | |
| JP2645554B2 (en) | Miscarriage / stillbirth prevention agent | |
| Farid et al. | Treatment of urinary schistosomiasis with Astiban and with Astiban acid in oil: a quantitative evaluation | |
| Moore | Treatment of syphilis with penicillin | |
| SU1194418A1 (en) | Method of treatment of children having purulent destructive pneumonia | |
| Mendels | Transient toxicity with carphenazine hydrochloride | |
| US3787494A (en) | N-(n,n-diethylenediamine) substituted amides of 1-aminocyclopentanecarboxylic acid | |
| Saner, RG & Fehler | A case of Q fever contracted on the Witwatersrand | |
| Hudnell et al. | Gamma globulin in experimental herpes simplex keratitis | |
| SU1676628A1 (en) | Non-alcoholic agent "glycal" | |
| Yeung et al. | Immunosuppressive activities of two abortifacient proteins-α-and β-momorcharin |